Tridem Bioscience

Executive Summary

Tridem Bioscience is a private Austrian biopharmaceutical company founded in 2016 and headquartered in Vienna, focusing on autoimmune and inflammatory diseases. The company develops novel vaccine-based immunotherapies designed to modulate the immune system, offering both therapeutic and diagnostic solutions. While specific pipeline details and funding history remain undisclosed, Tridem's approach leverages vaccine principles to induce immune tolerance or correct dysregulation, targeting a large market opportunity. The company operates in a competitive landscape but with limited public information, its progress and valuation are uncertain.

Upcoming Catalysts (preview)

• TBDDisclosure of lead therapeutic candidate and preclinical data30% success
• TBDSeries A or strategic investment round40% success
• TBDPartnership with academic or industry collaborators50% success